Effectiveness of Biological Treatment on Hip Involvement in Inflammatory Rheumatic Diseases.

Area of Science:

• Rheumatology
• Immunology
• Orthopedics

Background:

• Hip involvement is a common and debilitating manifestation of chronic inflammatory rheumatic diseases.
• Severe hip disease significantly impacts patient function, quality of life, and can lead to disability.
• While arthroplasty is effective, conservative strategies and biological treatments are increasingly utilized.

Purpose of the Study:

• To review current evidence on the efficacy of biological treatments for hip involvement in inflammatory rheumatic diseases.
• To summarize the impact of these therapies on symptoms, function, and structural damage.
• To identify gaps in knowledge regarding hip involvement in these conditions.

Main Methods:

• A narrative review of the PubMed database was performed.
• Included case reports, case series, and original articles published up to 2024.
• Focused on studies evaluating biological treatments for hip manifestations.

Main Results:

• Tumor necrosis factor-alpha (TNFα) inhibitors effectively alleviate hip symptoms, improve function, and stabilize radiographic damage.
• Tocilizumab shows potential in halting and reducing hip damage in systemic juvenile idiopathic arthritis.
• Interleukin-17/Interleukin-23 (IL-17/IL-23) axis inhibitors relieve hip pain in spondyloarthritis, but their effect on structural damage is unclear.

Conclusions:

• Biological therapies, particularly TNFα inhibitors, demonstrate significant benefits for hip involvement in inflammatory rheumatic diseases.
• Tocilizumab and IL-17/IL-23 inhibitors show promise but require further investigation for hip structural damage.
• Current data on hip involvement in these diseases are limited, emphasizing the need for more extensive research.